ECTRIMS eLearning

Gray and white matter brain pathology in highly active multiple sclerosis patients
Author(s): ,
F. Sanchez
Affiliations:
Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
,
J. Rojas
Affiliations:
Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
,
L. Patrucco
Affiliations:
Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
,
J. Miguez
Affiliations:
Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
E. Cristiano
Affiliations:
Centro de Esclerosis Múltiple de Buenos Aires, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
ECTRIMS Learn. Rojas J. 10/10/18; 229342; EP1504
Juan Rojas
Juan Rojas
Contributions
Abstract

Abstract: EP1504

Type: Poster Sessions

Abstract Category: Pathology and pathogenesis of MS - MRI and PET

The objective of the study was to analyze white matter (WM) and gray matter (GM) pathology in highly active MS (HAMS) vs. no-HAMS patients.
Methods:
we included patients with MS older than 18 years and with at least 2 years of follow up. HAMS was defined as patients with 1 relapse in the previous year and at least 1 T1 Gd+ lesion or 9 or more T2 lesions, while on therapy with other DMDs, or patients with 2 or more relapses in the previous year, whether on DMD treatment or not. Only patients naïve to previous treatment were included. High-resolution T1-3D weighted MRI scans were acquired at baseline and every 12 months for 2 years. Brain volume measures were determined on 3D T1-WI. At baseline, whole brain, GM and WM tissue volumes, were calculated using the SIENAX method, whereas for longitudinal changes, the SIENA method was used to calculate the percentage brain volume change (PBVC), and the SIENAX multi-time point method was used to obtain GM volume and WM volume changes. Between-group differences of volume analysis were assessed by logistic regression analysis (p < 0.05 significant).
Results:
64 patients, mean age 38.4 years, 35 (57%) women were included. A total of 14 (21%) were classified as HAMS. At baseline, HAMS patients showed lower GM and WM volume compared with no-HAMS (p=0.001 and p=0.01 respectively). All patients received fingolimod to treat their disease. During the follow up, HAMS showed a higher decrease in the percent of gray matter volume change compared with no-HAMS (-0.61 vs. - 0.77 p< 0.001) but a similar percent of white matter change between groups were found (-0.43 vs. -0.50 p=0.04).
Conclusion: HAMS patients developed similar rates of WM but different rates of GM atrophy over 24 months, compared to non-HAMS patients.
Disclosure: The study was done without external support

Abstract: EP1504

Type: Poster Sessions

Abstract Category: Pathology and pathogenesis of MS - MRI and PET

The objective of the study was to analyze white matter (WM) and gray matter (GM) pathology in highly active MS (HAMS) vs. no-HAMS patients.
Methods:
we included patients with MS older than 18 years and with at least 2 years of follow up. HAMS was defined as patients with 1 relapse in the previous year and at least 1 T1 Gd+ lesion or 9 or more T2 lesions, while on therapy with other DMDs, or patients with 2 or more relapses in the previous year, whether on DMD treatment or not. Only patients naïve to previous treatment were included. High-resolution T1-3D weighted MRI scans were acquired at baseline and every 12 months for 2 years. Brain volume measures were determined on 3D T1-WI. At baseline, whole brain, GM and WM tissue volumes, were calculated using the SIENAX method, whereas for longitudinal changes, the SIENA method was used to calculate the percentage brain volume change (PBVC), and the SIENAX multi-time point method was used to obtain GM volume and WM volume changes. Between-group differences of volume analysis were assessed by logistic regression analysis (p < 0.05 significant).
Results:
64 patients, mean age 38.4 years, 35 (57%) women were included. A total of 14 (21%) were classified as HAMS. At baseline, HAMS patients showed lower GM and WM volume compared with no-HAMS (p=0.001 and p=0.01 respectively). All patients received fingolimod to treat their disease. During the follow up, HAMS showed a higher decrease in the percent of gray matter volume change compared with no-HAMS (-0.61 vs. - 0.77 p< 0.001) but a similar percent of white matter change between groups were found (-0.43 vs. -0.50 p=0.04).
Conclusion: HAMS patients developed similar rates of WM but different rates of GM atrophy over 24 months, compared to non-HAMS patients.
Disclosure: The study was done without external support

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies